Dr. Jin introduced Wnt signaling cascade into the GLP-1 field. His team generated functional knockdown tools and 4 transgenic mouse lines in exploring how Wnt effectors mediate functions of metabolic hormones (i.e. GLP-1, insulin and estradiol) in pancreas, liver, brain and adipose tissues. The investigations enabled him to build up the theory that developmental Wnt signaling pathway effectors (with β-cat/TCF7L2 as an example) mediate functions of metabolic and other hormones during adulthood. Mechanistically, these hormones temporally and spatially control expression of TCF family members and modify β-cat via different protein kinases. As functional studies on GLP-1 led to the development of novel therapeutic agents for diabetes, such as liraglutide/Victorza, Dr. Jin’s team conducted unique translational studies on GLP-1 and based drugs, including pancreatic and extra-pancreatic function of GLP-1 short fragment, function of GLP-1 based drugs in the liver, lung and adipose tissues. He collaborated with others to study the combined effect of GABA and GLP-1 in treating type 1 diabetes (T1D), and dietary polyphenols in the prevention and treatment of metabolic disorders. Dr. Jin has authored more than 120 peer reviewed publications. His team is currently exploring how hepatic Wnt signaling cascade mediates GLP-1, FGF21 and estradiol in metabolic homeostasis, GLP-1 receptor mediated function of GABA in treating T1D and lung injury.